ABT deferred discussion of Humira to ABBV’s CC on Jan 30. IMO, the 25% YoY growth can be attributed to: i) new approved indications; ii) price increases in the US; and ii) strong growth in emerging markets. We’ll know more about this next week.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”